Clinical characteristics of Graves’ disease following COVID-19 infection or vaccination: a multicenter case-control study
Turkish Journal of Medical Sciences · 12.12.2025 · 55 (6) · 1381-1393
DOI: 10.55730/1300-0144.6096 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 12.12.2025. Verfasst von Asena Gökçay Canpolat und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye. Hauptthemen laut MEDLINE: COVID-19, Graves Disease, COVID-19 Vaccines, Vaccination. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aim: To describe Graves’ Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control). Materials and methods: Included in this multicenter matched case–control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID.
Results
The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TRAb) titers (p < 0.001) compared with the control group (3.5-fold), as well as a higher proportion of recurrent cases. At baseline, the COVID group had higher free triiodothyronine (fT3) levels than the other groups. Graves orbitopathy (GO) was observed in 60 patients (12.6%), with a higher frequency in classical GD (18.4%). At baseline, the variables associated with thyrotoxicosis severity (defined as fT3 levels) were younger age, higher thyroid gland volume (TGV), and etiology, with the COVID and, to a lesser extent, VAC groups presenting with higher fT3 levels. The variables associated with GO were higher TGV, TRAb titers, and smoking, while no association with etiology was identified.
Conclusion
The clinical course was similar in all groups other than in some laboratory findings. Although the frequency of GO associated with COVID and VAC was lower, the proportion of cases with a Clinical Activity Score of ≥3 was higher compared to GD. This pattern suggests a potentially stronger immunologic trigger in these cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkiye.
- Clinic of Endocrinology and Metabolic Diseases, İskenderun Gelişim Hospital, Hatay, Turkiye.
- Department of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkiye.
- Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Ankara Yüksek İhtisas University, Ankara, Turkiye.
- Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Uşak University, Uşak, Turkiye.
- Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, Marmara University, İstanbul, Turkiye.
ORCID-Profile: Asena Gökçay Canpolat, Kemal Ağbaht, Atilla Halil Elhan, Mustafa Cesur, Ziynet Alphan Üç, Seçkin Akçay, Hülya Iliksu Gözü, Mehmet Aşik, Hayri Bostan, Bekir Uçan, Tuğçe Şah Ünal, Merve Yilmaz, Ayşe Kubat Üzüm, Mehmet Çağrı Ünal, Cüneyd Anil, Ümmü Mutlu, Nurcan Ince, Sevgül Faki, Güven Barış Cansu, Mehmet Sercan Ertürk, Ayten Oğuz, Mustafa Aydemir, Şefika Burçak Polat, Oya Topaloğlu, Reyhan Ersoy, Bekir Çakir, Ayşe Merve Ok, Ersen Karakiliç, Muhittin Yalçin, Yusuf Kayhan, Kader Uğur, Dilek Yazici, Alper Gürlek, Tülay Omma, Emre Sedar Saygili, Adnan Batman, Banu Kara, Göknur Yorulmaz, Bahri Evren, Füsun Baloş Törüner, Bülent Okan Yildiz, Murat Faik Erdoğan, Faruk Alagöl, Erman Çakal, Mustafa Şahin
Zitieren
APA
Gökçay Canpolat, A., Ağbaht, K., Elhan, A. H., Cesur, M., Alphan Üç, Z., Akçay, S., Iliksu Gözü, H., Aşik, M., Bostan, H., Uçan, B., Şah Ünal, T., Yilmaz, M., Kubat Üzüm, A., Ünal, M. Ç., Anil, C., Mutlu, Ü., Ince, N., Faki, S., Cansu, G. B., …, & Şahin, M. (2025). Clinical characteristics of Graves’ disease following COVID-19 infection or vaccination: a multicenter case-control study. Turkish Journal of Medical Sciences, 55(6), 1381-1393. https://doi.org/10.55730/1300-0144.6096
Vancouver
Gökçay Canpolat A, Ağbaht K, Elhan AH, Cesur M, Alphan Üç Z, Akçay S, et al. Clinical characteristics of Graves’ disease following COVID-19 infection or vaccination: a multicenter case-control study. Turkish Journal of Medical Sciences. 2025;55(6):1381-1393. doi:10.55730/1300-0144.6096
BibTeX
@article{GkayCanpolat2025,
author = {Gökçay Canpolat, Asena and Ağbaht, Kemal and Elhan, Atilla Halil and Cesur, Mustafa and Alphan Üç, Ziynet and Akçay, Seçkin and Iliksu Gözü, Hülya and Aşik, Mehmet and Bostan, Hayri and Uçan, Bekir and Şah Ünal, Tuğçe and Yilmaz, Merve and Kubat Üzüm, Ayşe and Ünal, Mehmet Çağrı and Anil, Cüneyd and Mutlu, Ümmü and Ince, Nurcan and Faki, Sevgül and Cansu, Güven Barış and Ertürk, Mehmet Sercan and Oğuz, Ayten and Aydemir, Mustafa and Polat, Şefika Burçak and Topaloğlu, Oya and Ersoy, Reyhan and Çakir, Bekir and Ok, Ayşe Merve and Karakiliç, Ersen and Yalçin, Muhittin and Kayhan, Yusuf and Uğur, Kader and Yazici, Dilek and Gürlek, Alper and Omma, Tülay and Saygili, Emre Sedar and Batman, Adnan and Kara, Banu and Yorulmaz, Göknur and Evren, Bahri and Baloş Törüner, Füsun and Yildiz, Bülent Okan and Erdoğan, Murat Faik and Alagöl, Faruk and Çakal, Erman and Şahin, Mustafa},
title = {Clinical characteristics of Graves’ disease following COVID-19 infection or vaccination: a multicenter case-control study},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {6},
pages = {1381--1393},
doi = {10.55730/1300-0144.6096}
}
EUVIMED